Open for inclusion

A Phase IB/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Cancer type: Myeloma

Phase: I/II

Principal Investigator: Schjesvold Fredrik

Country: NO

Keywords: Norway, Oslo,

Status: Open for inclusion

Link to